Visit Booth #1222, November 11–15 at the Boston Convention and Exhibition Center
Carlsbad, CA— DCN Dx, a provider of IVD clinical research and regulatory consulting services, as well as lateral flow diagnostics development and manufacturing, will exhibit at the AMP 2025 Annual Meeting & Expo, taking place November 11–15 at the Boston Convention and Exhibition Center in Boston, Massachusetts.
The company will be located at Booth #1222, where attendees can connect with DCN Dx experts to explore how its integrated IVD CRO services and point-of-care CDMO expertise accelerate diagnostic development.
In addition to its booth presence, DCN Dx’s Vice President of Clinical Research, Emily Friedland, will deliver an Innovation Spotlight presentation on Friday, November 14, from 12:40–1:10 PM. Titled A 360° Approach to Aligning Clinical and Regulatory Strategy in IVD Development, the talk will outline a proven framework for integrating clinical and regulatory planning across the IVD lifecycle. Drawing on her experience leading regulatory and clinical strategy at DCN Dx, Friedland will highlight common pitfalls such as rework, delays, and costly amendments, and demonstrate how cross-functional alignment in protocol design, usability, biostatistics, and global submission strategy can prevent them for faster, more predictable outcomes.
DCN Dx offers comprehensive services spanning the full IVD product lifecycle—from early-stage assay design through full-service clinical research and regulatory affairs. Its regulatory affairs team provides complete support for U.S. and international approvals, including strategy development, submission preparation, agency interactions, trial oversight, and post-market compliance. This CRO offering ensures diagnostic developers a seamless and coordinated path to market.
“AMP is a cornerstone event for advancing molecular pathology and in vitro diagnostics,” said Mitzi Rettinger, DCN Dx’s Chief Revenue Officer. “We’re excited not only to meet with innovators at our booth, but also to have Emily Friedland share her expertise on aligning clinical and regulatory strategy, an area where DCN Dx consistently helps clients accelerate time to market.”
AMP 2025 is the premier molecular diagnostics meeting, bringing together thousands of laboratory professionals, clinicians, researchers, and industry partners to share scientific advances, foster collaboration, and explore innovations in molecular medicine and diagnostics.
Attendees are encouraged to schedule a meeting in advance to ensure dedicated time with DCN Dx subject matter experts during the conference.
To request a meeting with DCN Dx at AMP 2025, visit https://shorturl.at/WvrfX.
About DCN Dx
DCN Dx, based in Carlsbad, California, specializes in lateral flow diagnostics development and manufacturing, and IVD regulatory consulting and clinical research. DCN Dx’s multidisciplinary CDMO specializes in creating tailored assay systems, consumables, and instruments for point-of-use applications, with a particular expertise in lateral flow assays. Their clinical research and regulatory services group specializes in the planning, execution, and oversight of IVD clinical trials, inclusive of clinical operations, data management, and biostatistics, and regulatory affairs services.
DCN Dx’s personalized approach to IVD product development and clinical trials has supported hundreds of programs and clients. They can oversee every stage from concept to assay development and platform integration, through clinical trials to manufacturing or only handle the aspects you request. In addition to lateral flow assays, DCN Dx’s clinical research expertise extends to any in vitro diagnostic, all with a focus on innovation, usability, and performance. With a commitment to quality, customer satisfaction, and industry-leading expertise, DCN Dx is setting the benchmark for excellence in IVD services. To learn more about how we can support your diagnostic needs, visit dcndx.com
